Abstract

Aim & Objective: Demographic datas like the patients age, gestational age, admission BP, blood and urine investigation, neuroimaging, Management, mode of delivery, neonatal and maternal outcomes were analysed in patients presenting with eclampsia in a tertiary care centre.

Introduction: The onset of convulsions in a woman with pre eclampsia that cannot be attributed to other causes is termed eclampsia. Eclampsia is a major cause of maternal and neonatal morbidity and mortality. Magnesium sulfate is the drug of choice for reducing the rate of eclampsia and also to prevent recurrent convulsions in eclampsia.

Materials and Methods: The study was conducted retrospectively on cases presenting with eclampsia in the OBG department, Government Rajaji Hospital for a period of 6 months from July 2019 to December 2019.

Results: During the 6 month study period, total 26 cases of eclampsia was reported out of 5843 deliveries (0.4%). Total 657 cases of hypertensive disorders of pregnancy (11.2%) was reported out of which 65 cases were severe pre-eclampsia (9.8%). 65% (11) of eclampsia presented as Antepartum eclampsia, 30.7%(11) cases presented as postpartum eclampsia, 3.8%(1) case as intrapartum eclampsia. One case presented as both antepartum and postpartum eclampsia. No case of maternal mortality was reported during the study period.

Conclusion: Early detection of cases of pre-eclampsia and imminent eclampsia, proper evaluation and treatment with anti-hypertensives and Magnesium sulphate will reduce the occurrence of eclampsia. Multidisciplinary approach in a tertiary care centre can reduce the maternal mortality and morbidity. Proper knowledge of management of eclampsia can reduce the mortality. IV labetalol and its careful use is mandatory. Perinatal mortality is high mainly because of prematurity.

• 1.   Mayrink J, Costa ML, Cecatti JG. Pre eclampsi in 2018: revisiting concepts, physiopathology, and prediction. Scientific World Journal. 2018;2018:6268276.
• 2.   Magley M, Hinson MR. Eclampsia. Treasure Island, FL: Stat Pearls Publishing; 2022.
• 3.   Gasnier R. Eclampsia: An overview clinical presentation, diagnosis and management. MOJWH. 2016;3:1–.
• 4.   Tabesh M, Salehi-Abargouei A, Tabesh M, Esmaillzadeh A. Maternal vitamin D status and risk of pre-eclampsia: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98:3165–73.
• 5.   Sibai BM, Sarinoglu C, Mercer BM. Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis. Am J Obstet Gynecol. 1992;166:1757–61.
• 6.   Fish R. The HEL P Syndrome: Case report and review of the literature. J Emerg Med. 1993;11:169–74.
• 7.   HELP syndrome [Internet]. 2021 [cited 2025 Dec 3
• 8.   Pritchard JA, Weisman R, Ratnoff OD, Vosburgh GJ. Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. N Engl J Med. 1954;250:89–98.
• 9.   Curtin WM, Weinstein L. A review of HELP syndrome. J Perinatol. 1999;19:138-43.
• 10.   Moodley J, Kalane G. A review of the management of eclampsia: practical issues. Hypertens Pregnancy. 2006;25:47–62.

Data Sharing Statement

Funding